ContraFect Corporation Stock News

Read more

YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the SVB Leerink 11 th Annual Global Healthcare Conference, which is being held virtually from February 14–18, 2022. The fireside chat will be held on Thursday, February 17, 2022 at 10:00 AM ET. Read more

Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT ) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH ) shares climbed 62.5% to close at $19.50 following its recent listing on NASDAQ. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL ) surged 51.4% to settle at $1.62. Kaival Brands Innovations recently announced the U.S. Court of Appeals for the Eleventh Circuit has granted a judicial stay of the marketing denial order previously issued by the FDA to Bidi Vapor in September 2021. Origin Agritech Limited (NASDAQ: SEED ) gained 34.5% to settle at $6.39 after the company said it expects FY22 sales to exceed RMB150 million. Bakkt Holdings, Inc. (NASDAQ: BKKT ) shares jumped 34% to close at $5.80. Luokung Technology Corp. (NASDAQ: LKCO ) gained 24.3% to close at $0.63. Luokung recently announced the receipt of Nasdaq notification regarding minimum bid price deficiency. Navidea Biopharmaceuticals, Inc. (NYSE: NAVB ) surged 23.2% to settle at $0.8870 after the company announced a research agreement with the University of Pennsylvania evaluating Tc99m tilmanocept as a prognostic marker for glioblastoma. Read more

Photo by freestocks on Unsplash Dr. Roger Pomerantz, Chairman and CEO of ContraFect Corp. (NASDAQ: CFRX ), was a guest speaker at Full story available on Benzinga.com Read more

Aadi Bioscience (NASDAQ:AADI) and ContraFect (NASDAQ:CFRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation. Valuation & Earnings This table compares Aadi Bioscience and ContraFects revenue, earnings per share (EPS) and [] Read more

Wall Street brokerages expect that ContraFect Co. (NASDAQ:CFRX) will report earnings of ($0.28) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for ContraFects earnings, with the highest EPS estimate coming in at ($0.26) and the lowest estimate coming in at ($0.30). ContraFect reported earnings of ($0.52) per share [] Read more

ContraFect Co. (NASDAQ:CFRX) Analysts at Zacks Investment Research upped their FY2021 earnings estimates for shares of ContraFect in a note issued to investors on Tuesday, November 30th. Zacks Investment Research analyst D. Bautz now expects that the biotechnology company will earn ($0.71) per share for the year, up from their previous estimate of ($0.82). [] Read more

ContraFect Corporation (NASDAQ:CFRX) concluded the trading at $2.86 on Friday, December 03 with a fall of -9.49% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.16 and 5Y monthly beta was reading 0.97. Considering stocks 52-week price range provides that CFRX ContraFect Corporation (CFRX) Volatility Hits 14.06% : Keep Your Head Up Read More » Read more

Northern Trust Corp decreased its stake in shares of ContraFect Co. (NASDAQ:CFRX) by 77.3% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 58,892 shares of the biotechnology companys stock after selling 200,660 shares during the period. Northern Trust Corps holdings in ContraFect were worth $259,000 at the end of the most recent [] Read more

ContraFect Corporation (NASDAQ:CFRX) traded at $3.41 at close of the session on Tuesday, 11/30/21, made an upward move of 5.90% on its previous days price. Looking at the stock we see that its previous close was $3.22 and the beta (5Y monthly) reads 0.97 with the days price range being $3.20 $4.2799. In terms What Does ContraFect Corporations (NASDAQ: CFRX) Future Hold? Read More » Read more

ContraFect Co. (NASDAQ:CFRX) Equities research analysts at SVB Leerink raised their FY2021 EPS estimates for shares of ContraFect in a report released on Monday, November 15th. SVB Leerink analyst R. Ruiz now expects that the biotechnology company will post earnings per share of ($0.75) for the year, up from their prior forecast of ($0.95). [] Read more

ContraFect (NASDAQ:CFRX) released its quarterly earnings results on Monday. The biotechnology company reported ($0.13) EPS for the quarter, topping analysts consensus estimates of ($0.28) by $0.15, Fidelity Earnings reports. Shares of NASDAQ:CFRX traded down $0.29 during trading hours on Wednesday, hitting $3.48. The companys stock had a trading volume of 86 shares, compared to its [] Read more

Read more

YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the third quarter ended September 30, 2021. Read more

Contrafect Corporation (NASDAQ:CFRX) Probability Sentiment SUMMARY Researchers have struggled with the problem of antibiotic resistance to bloodstream infection treatments for the past two decades. Approximately 70% of bacteria have developed a measure of resistance to at least one existing antibiotic. Yet because of robust antibiotic research 70 years ago, doctors [] Read more